EP4377292A4 - Water-soluble prodrugs, conjugates and their uses - Google Patents

Water-soluble prodrugs, conjugates and their uses

Info

Publication number
EP4377292A4
EP4377292A4 EP22848817.7A EP22848817A EP4377292A4 EP 4377292 A4 EP4377292 A4 EP 4377292A4 EP 22848817 A EP22848817 A EP 22848817A EP 4377292 A4 EP4377292 A4 EP 4377292A4
Authority
EP
European Patent Office
Prior art keywords
conjugates
water
soluble prodrugs
prodrugs
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22848817.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4377292A1 (en
Inventor
Doron Shabat
Ronit Satchi-Fainaro
Stanley Sweeney-Lasch
Carl Deutsch
Nir Berger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Ramot at Tel Aviv University Ltd
Original Assignee
Merck Patent GmbH
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH, Ramot at Tel Aviv University Ltd filed Critical Merck Patent GmbH
Publication of EP4377292A1 publication Critical patent/EP4377292A1/en
Publication of EP4377292A4 publication Critical patent/EP4377292A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP22848817.7A 2021-07-28 2022-07-20 Water-soluble prodrugs, conjugates and their uses Pending EP4377292A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL28520821 2021-07-28
PCT/IL2022/050782 WO2023007481A1 (en) 2021-07-28 2022-07-20 Water soluble prodrug, conjugates and uses thereof

Publications (2)

Publication Number Publication Date
EP4377292A1 EP4377292A1 (en) 2024-06-05
EP4377292A4 true EP4377292A4 (en) 2026-06-03

Family

ID=85086377

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22848817.7A Pending EP4377292A4 (en) 2021-07-28 2022-07-20 Water-soluble prodrugs, conjugates and their uses

Country Status (7)

Country Link
EP (1) EP4377292A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024532677A (cg-RX-API-DMAC10.html)
CN (1) CN117999254A (cg-RX-API-DMAC10.html)
AU (1) AU2022318483A1 (cg-RX-API-DMAC10.html)
CA (1) CA3226393A1 (cg-RX-API-DMAC10.html)
IL (1) IL310354A (cg-RX-API-DMAC10.html)
WO (1) WO2023007481A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4566631A1 (en) * 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020188061A1 (en) * 2019-03-19 2020-09-24 Paul Scherrer Institut Transglutaminase conjugation method with a glycine based linker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531620A (ja) * 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド システイン操作抗体及びコンジュゲート
KR102710962B1 (ko) * 2017-07-04 2024-09-27 주식회사 인투셀 절단성 링커를 포함하는 화합물 및 이들의 용도
AU2019365238A1 (en) * 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020188061A1 (en) * 2019-03-19 2020-09-24 Paul Scherrer Institut Transglutaminase conjugation method with a glycine based linker

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CONILH LOUISE ET AL: "Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform", PHARMACEUTICALS, vol. 14, no. 3, 9 March 2021 (2021-03-09), pages 247, XP055953984, ISSN: 1424-8247, DOI: 10.3390/ph14030247 *
KUMAR RAJESH ET AL: "Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor", BIOMATERIALS ELSEVIER, AMSTERDAM, NL, vol. 104, 14 July 2016 (2016-07-14), pages 119 - 128, XP029681211, ISSN: 0142-9612, DOI: 10.1016/J.BIOMATERIALS.2016.07.010 *
See also references of WO2023007481A1 *
VINEBERG JACOB G. ET AL: "Design, Synthesis, and Biological Evaluations of Tumor-Targeting Dual-Warhead Conjugates for a Taxoid-Camptothecin Combination Chemotherapy", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 13, 5 June 2014 (2014-06-05), pages 5777 - 5791, XP055954712, ISSN: 0022-2623, DOI: 10.1021/jm500631u *
YAMAZAKI CHISATO M. ET AL: "Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance", NATURE COMMUNICATIONS, vol. 12, no. 1, 10 June 2021 (2021-06-10), XP055940303, DOI: 10.1038/s41467-021-23793-7 *

Also Published As

Publication number Publication date
AU2022318483A1 (en) 2024-02-22
EP4377292A1 (en) 2024-06-05
CN117999254A (zh) 2024-05-07
WO2023007481A1 (en) 2023-02-02
IL310354A (en) 2024-03-01
JP2024532677A (ja) 2024-09-10
CA3226393A1 (en) 2023-02-02

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240227

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07C0211460000

Ipc: A61K0047680000

A4 Supplementary search report drawn up and despatched

Effective date: 20260506

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/68 20170101AFI20260429BHEP

Ipc: A61P 35/00 20060101ALI20260429BHEP

Ipc: C07D 491/22 20060101ALI20260429BHEP

Ipc: C07K 16/32 20060101ALI20260429BHEP

Ipc: C07C 69/00 20060101ALI20260429BHEP

Ipc: C07C 211/46 20060101ALI20260429BHEP

Ipc: C07K 16/00 20060101ALI20260429BHEP